Efavirenz Metabolism and CNS Toxicity in Ugandan Children: CYP2B6 Genotype Impact

Supplementary file 5 from a 2015-2016 study by Sandra Soeria-Atmadja, published on figshare. The dataset likely contains plasma metabolite profiles and genotype data for 99 Ugandan children aged 3-12 years, collected over 24 weeks after initiating efavirenz-based antiretroviral therapy. It was last updated on 2026 04 24.

Use Cases

• Modeling the association between CYP2B6 metabolizer phenotype and efavirenz metabolite ratios based on described plasma measurements.
• Investigating the link between high efavirenz plasma concentrations (>4,000 ng/mL) and CNS adverse effects as described in the study results.
• Analyzing patterns of drug autoinduction over time in extensive metabolizers based on the longitudinal sampling mentioned.
• Comparing the distribution of conjugated vs. unconjugated metabolite forms across different metabolizer phenotypes.

Strengths

• Includes longitudinal plasma sampling at 2, 6, 12, and 24 weeks for 99 participants.
• Quantifies multiple efavirenz metabolites (8-OH-EFV, 7-OH-EFV, EFAdeg) in both conjugated and unconjugated forms.
• Links clinical CNS symptom questionnaire data with pharmacokinetic and genetic (CYP2B6/CYP2A6 SNP) data.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (37.0 KB), indicating limited scope, likely a summary document.

Provenance

Source

Sandra Soeria-Atmadja, via figshare.

Collection Method

Prospective clinical study using liquid chromatography high-resolution tandem mass spectrometry and genotyping.

Time Range

Data collection occurred in 2015–2016.

Freshness

Last updated 2026-04-24 05:40:40; freshness should be verified.

Geography

Study participants were Ugandan children.